Technology

Marcadia's proprietary synthetic peptide chemistry is directed towards established molecular targets for the treatment of diabetes and obesity. The company's unique chemistry technology enables improved pharmacokinetics, improved physical chemical properties, and increased potency.

Development Programs

Marcadia has a broad portfolio which includes multiple clinical-stage programs for treatment of diabetes and obesity.

In the News

New Targets, Dual Agonists Increase Possibilities for Treating Diabetes

August 16, 2010 - Drug Discovery & Development

Lilly Partners with Marcadia

July 4, 2010 - Inside Indiana with Gerry Dick

Lilly Partners with Marcadia for Injectable Pens to Treat Hypoglycemia

June 30, 2010 - The Pink Sheet